Research and Development Investment: Genmab A/S vs Grifols, S.A.

Genmab's R&D spending outpaces Grifols by 1,400% in a decade.

__timestampGenmab A/SGrifols, S.A.
Wednesday, January 1, 2014505679000180753000
Thursday, January 1, 2015487656000224193000
Friday, January 1, 2016660876000197617000
Sunday, January 1, 2017874278000288320000
Monday, January 1, 20181431159000240661000
Tuesday, January 1, 20192386000000276018000
Wednesday, January 1, 20203137000000294216000
Friday, January 1, 20214181000000354881000
Saturday, January 1, 20225562000000361140000
Sunday, January 1, 20237630000000330551000
Monday, January 1, 20249748000000
Loading chart...

Infusing magic into the data realm

A Decade of Innovation: Genmab A/S vs Grifols, S.A.

In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal. Over the past decade, Genmab A/S has demonstrated a remarkable commitment to innovation, with its R&D expenses surging by over 1,400% from 2014 to 2023. This Danish biotech powerhouse has consistently prioritized groundbreaking research, culminating in a staggering 7.63 billion in R&D spending by 2023.

In contrast, Grifols, S.A., a Spanish pharmaceutical giant, has maintained a steady yet modest growth in R&D investments, increasing by approximately 83% over the same period. While Grifols' focus remains on its core competencies, the disparity in R&D spending highlights Genmab's aggressive pursuit of cutting-edge therapies.

This comparison underscores the diverse strategies within the biotech sector, where innovation and strategic investments shape the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025